Table 4 Comparison between normal and reduced BECN1 gene expression groups

Sex [n (%)]

 Females

6 (42.9%)

22 (61.1%)

1.363*

0.243

NS

 Males

8 (57.1%)

14 (38.9%)

Age (years)

 Mean ± SD

33.86 ± 15.92

58.44 ± 17.37

− 4.596^•

0.000

HS

 Range

(18–70)

(19–78)

Clinical data [n (%)]

 Fever

3(21.4%)

8(22.2%)

0.004*

0.951

NS

 Hepatomegaly

4(28.6%)

15(41.7%)

0.734*

0.392

 Splenomegaly

5(35.7%)

14(38.9%)

0.043*

0.836

 Lymphadenopathy

0(0.0%)

4(11.1%)

1.691*

0.193

TLC (× 10⁹/L) Median (IQR)

20.3 (13.3–35.4)

65.15 (37.3–83.05)

3.824^≠

0.000

HS

Hb (g/dl) Mean ± SD

8.09 ± 2.31

8.09 ± 1.92

0.002^•

0.999

NS

PLT (× 10⁹/L) Median(IQR)

41 (28–68)

30.5 (20–67.5)

− 0.908^≠

0.364

NS

PB blasts (%)Mean ± SD

40.71 ± 20.33

63.28 ± 21.64

− 3.364^•

0.002

HS

BM blasts (%)Mean ± SD

63.07 ± 22.17

80.58 ± 18.34

− 2.858^•

0.006

HS

 CD34 +

5 (35.7%)

28 (77.8%)

7.948*

0.005

HS

 CD117 +

5 (35.7%)

27 (75.0%)

6.752*

0.009

HS

 HLA-DR +

11 (78.6%)

32 (88.9%)

0.891*

0.345

NS

FAB subtypes [n (%)]

 M0

0 (0.0%)

5 (13.9%)

9.106*

0.105

NS

 M1

2 (14.3%)

8 (22.2%)

 M2

5 (35.7%)

15 (41.7%)

 M3

4 (28.6%)

1 (2.8%)

 M4

3 (21.4%)

4 (11.1%)

 M5

0 (0.0%)

3 (8.3%)

 Wild type NPM1

1 (7.1%)

4 (11.1%)

0.176*

0.675

NS

 Mutated NPM1 and FLT3-ITD

0 (0.0%)

2 (5.6%)

0.81*

0.368

NS

 FLT3-ITD mutation

0 (0.0%)

14 (38.9%)

7.562*

0.006

HS

 c-KIT mutation

2 (14.3%)

6 (16.7%)

0.043*

0.837

NS

 Favourable

9 (81.8%)

2 (18.2%)

20.314*

0.000

HS

 Intermediate

1 (10.0%)

9 (90.0%)

 Adverse

4 (13.8%)

25 (86.2%)

 Non- responders

4 (28.6%)

31 (86.1%)

15.892*

0.000

HS

 Responders

10(71.4%)

5 (13.9%)